Drugs / MINHAI PCV13
last change Oct 2021 re-read 2 minutes ago

MINHAI PCV13

Vaccine

Developed for
pneumonia
Investigated by
Beijing Minhai Biotechnology Co., Ltd · Jiangsu Province Centers for Disease Control and Prevention

Trials 1 · a red edge is where a trial was stopped

2017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT02494999 Jun 2016 → Dec 2018 pneumonia Jiangsu Province Centers for Disease Control and Prevention Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MINHAI PCV13 “A phase 3 clinical trial of MINHAI PCV13 in Chinese children aged from 7 months to 5 years old.” PMID 34706841 Oct 2021
Known as 13-valent pneumococcal conjugate vaccine “A new 13-valent pneumococcal conjugate vaccine (PCV13) with carrier tetanus toxoid and diphtheria toxoid was developed by MINHAI, aiming to prevent pneumococcus infection.” PMID 34706841 Oct 2021
Known as PCV13 “A new 13-valent pneumococcal conjugate vaccine (PCV13) with carrier tetanus toxoid and diphtheria toxoid was developed by MINHAI, aiming to prevent pneumococcus infection.” PMID 34706841 Oct 2021
Modality Vaccine “A new 13-valent pneumococcal conjugate vaccine (PCV13)” PMID 34706841 Oct 2021
Route Intramuscular “Single 0.5 ml dose will be given via intramuscular injection in Month 0,2,4 and 10” NCT02494999